Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
|Articles|August 10, 2020
Quiz: Detecting Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma
Author(s)Hannah Slater
In our liver cancer quiz, you’ll get a chance to test your knowledge on recurrence following resection in patients with intrahepatic cholangiocarcinoma and the new tools being developed to aid in treating this patient population.
Advertisement
1. Approximately how many patients with intrahepatic cholangiocarcinoma (ICC) will experience a recurrence following resection?
a. 30% to 50%
b. 10% to 30%
c. 50% to 70%
d. 60% to 90%
Advertisement
Related to this article
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 PERSEUS study.
Ethan B. Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in cholangiocarcinoma.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma.
In the phase 2 IBEX trial, iberdomide plus subcutaneous daratumumab post-transplant maintenance improved MRD status in patients with multiple myeloma.
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small cell lung cancer.
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
5